Skip to main content
Top
Published in: Clinical Pharmacokinetics 8/2023

Open Access 23-06-2023 | Pharmacokinetics | Original Research Article

Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs

Authors: J. M. Janssen, D. Damoiseaux, J. G. C. van Hasselt, F. C. H. Amant, K. van Calsteren, J. H. Beijnen, A. D. R. Huitema, T. P. C. Dorlo

Published in: Clinical Pharmacokinetics | Issue 8/2023

Login to get access

Abstract

Background and Objective

As a result of changes in physiology during pregnancy, the pharmacokinetics (PK) of drugs can be altered. It is unclear whether under- or overexposure occurs in pregnant cancer patients and thus also whether adjustments in dosing regimens are required. Given the severity of the malignant disease and the potentially high impact on both the mother and child, there is a high unmet medical need for adequate and tolerable treatment of this patient population. We aimed to develop and evaluate a semi-physiological enriched model that incorporates physiological changes during pregnancy into available population PK models developed from non-pregnant patient data.

Methods

Gestational changes in plasma protein levels, renal function, hepatic function, plasma volume, extracellular water and total body water were implemented in existing empirical PK models for docetaxel, paclitaxel, epirubicin and doxorubicin. These models were used to predict PK profiles for pregnant patients, which were compared with observed data obtained from pregnant patients.

Results

The observed PK profiles were well described by the model. For docetaxel, paclitaxel and doxorubicin, an overprediction of the lower concentrations was observed, most likely as a result of a lack of data on the gestational changes in metabolizing enzymes. For paclitaxel, epirubicin and doxorubicin, the semi-physiological enriched model performed better in predicting PK in pregnant patients compared with a model that was not adjusted for pregnancy-induced changes.

Conclusion

By incorporating gestational changes into existing population pharmacokinetic models, it is possible to adequately predict plasma concentrations of drugs in pregnant patients which may inform dose adjustments in this population.
Literature
1.
go back to reference de Haan J, Verheecke M, Van Calsteren K, Van CB, Shmakov RG, Gziri MM, et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncol. 2018;19:337–46.CrossRefPubMed de Haan J, Verheecke M, Van Calsteren K, Van CB, Shmakov RG, Gziri MM, et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncol. 2018;19:337–46.CrossRefPubMed
2.
go back to reference European Medicines Agency (EMA). Guideline on the exposure to medicinal products during pregnancy: need for post-authorization data (2006). European Medicines Agency (EMA). Guideline on the exposure to medicinal products during pregnancy: need for post-authorization data (2006).
3.
go back to reference Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2012;51:365–96.CrossRefPubMed Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2012;51:365–96.CrossRefPubMed
4.
go back to reference Dallmann A, Ince I, Meyer M, Willmann S, Eissing T, Hempel G. Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy. Clin Pharmacokinet. 2017;56:1303–30.CrossRefPubMed Dallmann A, Ince I, Meyer M, Willmann S, Eissing T, Hempel G. Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy. Clin Pharmacokinet. 2017;56:1303–30.CrossRefPubMed
5.
go back to reference Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, Halaska MJ, Boere I, et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. N Engl J Med. 2015;373:1824–34.CrossRefPubMed Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, Halaska MJ, Boere I, et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. N Engl J Med. 2015;373:1824–34.CrossRefPubMed
6.
go back to reference Halaska MJ, Uzan C, Han SN, Fruscio R, Dahl Steffensen K, Van Calster B, et al. Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy. Int J Gynecol Cancer. 2019. (Online ahead of print). Halaska MJ, Uzan C, Han SN, Fruscio R, Dahl Steffensen K, Van Calster B, et al. Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy. Int J Gynecol Cancer. 2019. (Online ahead of print).
7.
go back to reference Maggen C, Dierickx D, Lugtenburg P, Laenen A, Cardonick E, Smakov R, et al. Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. Lancet Haematol. 2019;6:e551–61.CrossRefPubMed Maggen C, Dierickx D, Lugtenburg P, Laenen A, Cardonick E, Smakov R, et al. Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. Lancet Haematol. 2019;6:e551–61.CrossRefPubMed
8.
go back to reference Janssen JM, Van Calsteren K, Dorlo TPC, Halaska MJ, Fruscio R, Ottevanger P, et al. Population pharmacokinetics of docetaxel, paclitaxel, doxorubicin and epirubicin in pregnant women with cancer: a study from the International Network of Cancer, Infertility and Pregnancy (INCIP). Clin Pharmacokinet. 2021. (Online ahead of print). Janssen JM, Van Calsteren K, Dorlo TPC, Halaska MJ, Fruscio R, Ottevanger P, et al. Population pharmacokinetics of docetaxel, paclitaxel, doxorubicin and epirubicin in pregnant women with cancer: a study from the International Network of Cancer, Infertility and Pregnancy (INCIP). Clin Pharmacokinet. 2021. (Online ahead of print).
9.
go back to reference Vandenbroucke T, Verheecke M, Fumagalli M, Lok C, Amant F. Effects of cancer treatment during pregnancy on fetal and child development. Lancet Child Adolesc Health. 2017;1:302–10.CrossRefPubMed Vandenbroucke T, Verheecke M, Fumagalli M, Lok C, Amant F. Effects of cancer treatment during pregnancy on fetal and child development. Lancet Child Adolesc Health. 2017;1:302–10.CrossRefPubMed
10.
go back to reference Dallmann A, Mian P, den Anker J, Van AK. Clinical pharmacokinetic studies in pregnant women and the relevance of pharmacometric tools. Curr Pharm Des. 2019;25:483–95.CrossRefPubMed Dallmann A, Mian P, den Anker J, Van AK. Clinical pharmacokinetic studies in pregnant women and the relevance of pharmacometric tools. Curr Pharm Des. 2019;25:483–95.CrossRefPubMed
11.
go back to reference Nakai A, Sekiya I, Oya A, Koshino T, Araki T. Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonography. Arch Gynecol Obstet. 2002;266:25–9.CrossRefPubMed Nakai A, Sekiya I, Oya A, Koshino T, Araki T. Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonography. Arch Gynecol Obstet. 2002;266:25–9.CrossRefPubMed
12.
go back to reference Gibaldi M, McNamara PJ. Apparent volumes of distribution and drug binding to plasma proteins and tissues. Eur J Clin Pharmacol. 1989;13:373–80.CrossRef Gibaldi M, McNamara PJ. Apparent volumes of distribution and drug binding to plasma proteins and tissues. Eur J Clin Pharmacol. 1989;13:373–80.CrossRef
13.
go back to reference Koolen SLW, Oostendorp RL, Beijnen JH, Schellens JHM, Huitema ADR. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Br J Clin Pharmacol. 2010;69:465–74.CrossRefPubMedPubMedCentral Koolen SLW, Oostendorp RL, Beijnen JH, Schellens JHM, Huitema ADR. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Br J Clin Pharmacol. 2010;69:465–74.CrossRefPubMedPubMedCentral
14.
go back to reference Crombag M-RBS, de VriesSchultink AHM, Koolen SLW, Wijngaard S, Joerger M, Schellens JHM, et al. Impact of older age on the exposure of paclitaxel: a population pharmacokinetic study. Pharm Res. 2019;36:33.CrossRefPubMed Crombag M-RBS, de VriesSchultink AHM, Koolen SLW, Wijngaard S, Joerger M, Schellens JHM, et al. Impact of older age on the exposure of paclitaxel: a population pharmacokinetic study. Pharm Res. 2019;36:33.CrossRefPubMed
15.
go back to reference Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, et al. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet. 2007;46:1051–68.CrossRefPubMed Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, et al. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet. 2007;46:1051–68.CrossRefPubMed
16.
go back to reference Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson M. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol. 2006;58:143–56.CrossRefPubMed Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson M. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol. 2006;58:143–56.CrossRefPubMed
17.
go back to reference Bauer RJ. Nonmem users guide introduction to Nonmem 7.3.0. ICON Development Solutions, 2014. Bauer RJ. Nonmem users guide introduction to Nonmem 7.3.0. ICON Development Solutions, 2014.
18.
go back to reference RC Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2009. RC Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2009.
19.
go back to reference FDA Guidance for Industry. Pharmaockinetics in pregnancy—study design, data analysis, and impact on dosing and labeling. FDA Guidance (2004). FDA Guidance for Industry. Pharmaockinetics in pregnancy—study design, data analysis, and impact on dosing and labeling. FDA Guidance (2004).
20.
go back to reference FDA Guidance for Industry. establishing pregnancy exposure registries. FDA Guidance (2002). FDA Guidance for Industry. establishing pregnancy exposure registries. FDA Guidance (2002).
21.
go back to reference van Hasselt JGC, Van Calsteren K, Heyns L, Han S, MhallemGziri M, Schellens JHM, et al. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Ann Oncol. 2014;25:2059–65.CrossRefPubMed van Hasselt JGC, Van Calsteren K, Heyns L, Han S, MhallemGziri M, Schellens JHM, et al. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Ann Oncol. 2014;25:2059–65.CrossRefPubMed
Metadata
Title
Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs
Authors
J. M. Janssen
D. Damoiseaux
J. G. C. van Hasselt
F. C. H. Amant
K. van Calsteren
J. H. Beijnen
A. D. R. Huitema
T. P. C. Dorlo
Publication date
23-06-2023
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 8/2023
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-023-01263-1

Other articles of this Issue 8/2023

Clinical Pharmacokinetics 8/2023 Go to the issue